We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

3rd dose of Pfizer vaccine 95.6% effective against Delta, phase 3 results show

48 22 9
21.10.2021

A booster shot of the anti-COVID-19 vaccine developed by Pfizer-BioNTech is 95.6 percent effective against symptomatic infection, according to trial data published by the makers on Thursday.

The clinical phase three trial with “10,000 participants 16 years of age and older” showed “a relative vaccine efficacy of 95.6 percent against disease during a period when Delta was the prevalent strain,” the companies said in a statement.

The study presented the “first results” of a booster trial, with a third shot of the vaccine demonstrating a “favorable safety profile.”

“These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,” said Pfizer CEO Albert Bourla.

The preliminary results would be shared with regulatory agencies........

© The Times of Israel


Get it on Google Play